Vaxcyte (NASDAQ:PCVX) Price Target Raised to $122.00

Vaxcyte (NASDAQ:PCVX) had its target price upped by Needham & Company LLC from $110.00 to $122.00 in a research report report published on Monday morning, MarketBeat reports. They currently have a buy rating on the stock.

A number of other equities research analysts have also weighed in on the stock. Bank of America cut their target price on shares of Vaxcyte from $133.00 to $130.00 and set a “buy” rating on the stock in a research note on Monday, September 28th. Zacks Research raised shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Wall Street Zen raised shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. Guggenheim raised their price objective on shares of Vaxcyte from $116.00 to $125.00 and gave the stock a “buy” rating in a report on Monday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research report on Friday, October 2nd. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Vaxcyte presently has a consensus rating of “Moderate Buy” and a consensus target price of $108.60.

Vaxcyte Stock Up 0.4%

Shares of PCVX stock opened at $66.96 on Monday. The stock has a fifty day moving average of $59.56 and a 200 day moving average of $56.49. Vaxcyte has a 52 week low of $39.87 and a 52 week high of $90.75. The firm has a market capitalization of $9.96 billion, a price-to-earnings ratio of -8.78 and a beta of 1.23.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share for the quarter, beating the consensus estimate of ($2.06) by $0.09. During the same quarter in the prior year, the firm posted ($1.22) earnings per share. Equities research analysts anticipate that Vaxcyte will post -8.07 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Jim Wassil sold 18,000 shares of the business’s stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $86.74, for a total value of $1,561,320.00. Following the sale, the executive vice president directly owned 145,435 shares of the company’s stock, valued at $12,615,031.90. The trade was a 11.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Grant Pickering sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $55.65, for a total value of $111,300.00. Following the completion of the sale, the chief executive officer directly owned 133,215 shares in the company, valued at approximately $7,413,414.75. This represents a 1.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 92,890 shares of company stock valued at $6,320,569. Insiders own 3.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PCVX. Hsbc Holdings PLC lifted its position in Vaxcyte by 4.0% during the second quarter. Hsbc Holdings PLC now owns 4,151 shares of the company’s stock valued at $241,000 after purchasing an additional 159 shares during the period. Meeder Advisory Services Inc. boosted its holdings in Vaxcyte by 2.9% in the first quarter. Meeder Advisory Services Inc. now owns 8,335 shares of the company’s stock worth $484,000 after purchasing an additional 231 shares during the last quarter. IFP Advisors Inc grew its position in Vaxcyte by 72.8% in the 2nd quarter. IFP Advisors Inc now owns 560 shares of the company’s stock worth $33,000 after purchasing an additional 236 shares during the period. Northwestern Mutual Wealth Management Co. grew its position in Vaxcyte by 27.6% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,344 shares of the company’s stock worth $78,000 after purchasing an additional 291 shares during the period. Finally, Principal Financial Group Inc. raised its stake in Vaxcyte by 7.0% during the 1st quarter. Principal Financial Group Inc. now owns 5,275 shares of the company’s stock valued at $307,000 after buying an additional 343 shares during the last quarter. Institutional investors own 96.78% of the company’s stock.

More Vaxcyte News

Here are the key news stories impacting Vaxcyte this week:

• Positive Sentiment: Vaxcyte reported a positive Phase 3 result for its VAX-31 pneumococcal vaccine candidate in adults. The late-stage win strengthens the program’s regulatory and commercial prospects and prompted bullish commentary that the company had reached a potential “blue-sky” outcome. Vaxcyte leaps on positive Phase III trial of VAX-31
• Positive Sentiment: Analysts remain constructive following the clinical update. Needham assigned Vaxcyte a $122 price target, while BTIG reaffirmed its Buy rating, indicating substantial anticipated upside if VAX-31 continues to advance successfully. Vaxcyte given new price target at Needham
• Positive Sentiment: The company priced a financing consisting of $500 million of common stock and pre-funded warrants plus $500 million of 1.50% convertible senior notes due 2032. The proceeds should provide substantial funding for clinical development and commercialization preparations, while the relatively low coupon limits near-term interest expense. Vaxcyte announces pricing of concurrent offerings
• Neutral Sentiment: Options activity was unusually heavy, with investors purchasing 8,093 put contracts—about 259% of typical volume—suggesting increased hedging or bearish speculation, but not necessarily a change in the company’s fundamentals.
• Negative Sentiment: The equity issuance, pre-funded warrants and potentially convertible notes will increase the share count or create future dilution. The financing was priced at $64 per share, below the stock’s recent trading levels, contributing to selling pressure despite the positive trial news.
• Neutral Sentiment: Chief Accounting Officer Elvia Cowan and EVP Jim Wassil sold 19,000 and 18,000 shares, respectively, under pre-arranged Rule 10b5-1 plans. The transactions reduce their holdings but were scheduled sales and therefore provide limited insight into current management sentiment.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing vaccines to help prevent serious bacterial infections. The company uses its cell-free protein synthesis and advanced conjugation technologies to design vaccines intended to provide broad and durable protection while addressing limitations of existing vaccine products.

Vaxcyte’s lead programs are pneumococcal conjugate vaccine candidates, including VAX-24 and VAX-31, which are designed to target a broad range of pneumococcal serotypes.